Results of decision support system implementation for prescribing anticoagulants to patients with atrial fibrillation in hospital
- 作者: Chernov A.A.1,2, Kleymenova E.B.1,2,3, Sychev D.A.2, Yashina L.P.1,3, Nigmatkulova M.D.2, Otdelenov V.A.1,2, Payushchik S.A.1
-
隶属关系:
- General Medical Center of the Bank of Russia
- Russian Medical Academy of Continuous Professional Education
- Federal Research Center “Computer Science and Control”
- 期: 卷 92, 编号 8 (2020)
- 页面: 37-42
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/43539
- DOI: https://doi.org/10.26442/00403660.2020.08.000765
- ID: 43539
如何引用文章
全文:
详细
Background. In 8–19% of patients with atrial fibrillation (AF) with anticoagulant therapy (ACT), hemorrhagic complications occur, including due to excess doses of AC. At the same time, ACT is necessary for patients with AF, since anticoagulants effectively reduces the risk of ischemic stroke. To make a decision on the appointment of ACT, it is necessary to correlate the risks of ischemic stroke and bleeding, this requires knowledge of current clinical using ACT recommendations and instructions. Among patients admitted to hospital, 30% receive ACT, so increasing adherence to clinical recommendations for prescribing AC to patients with AF by doctors of various profiles is an urgent task.
Aim. To analyze the adherence of physicians to recommendations for prescribing ACT before and after the introduction of decision support system (DSS) in patients with AF in a multi-specialty hospital.
Materials and methods. A single-center non-randomized study with historical control to assess adherence to recommendations based on the analysis of medical prescriptions and the structure of drug errors in patients with AF in a multi-specialty hospital in Moscow before and after the introduction of DSS. Compliance with the recommendations of physicians was evaluated in the sections «indications /contraindications to AC» and «dosage regimen of AC». The presence of deviations from the clinical recommendations /instructions for medical use of AC was regarded as «management of the patient with non-compliance with recommendations». Physicians adherence level to recommendations was calculated as the ratio of cases of «compliance with recommendations» to the total number of cases.
Results. In the control and experimental groups, there was a significant increase in the proportion of POAC at discharge in comparison with admission to hospital: from 54.5 to 76.8% (p=0.0005) and from 63 to 85.7% (p=0.0002), respectively. However, only in the experimental group it was possible to significantly reduce the number of patients without a prescribed ACT (if there are indications) from 7.6 to 1% (p=0.04) in comparison with admission. During the study, it was possible to significantly increase physicians adherence level to the recommendations for the AC dosage regimen in patients with AF from 59% (44 discrepancies for 107 prescriptions) to 84.6% (16 discrepancies for 104 prescriptions); p<0.005. Before the introduction of the DSS, the analysis of drug prescriptions revealed 56 drug errors (0.5 errors per patient), after the introduction of the DSS, the number of drug errors significantly decreased to 21 (0.2 errors per patient); p<0.05. After the introduction of DSS, the number of sub-therapeutic doses of AC was reduced from 31 (27.7%) to 8 (7.6%); p<0.05.
Conclusion. The level of adherence to the recommendations for prescribing ACT to patients with AF in the hospital is high. The use of DSS increases the level of adherence to the recommendations on the AC dosage regimen in patients with AF, as well as eliminates errors in calculating the risk of ischemic stroke and systemic thromboembolic complications, and contributes to reducing the frequency of prescribing sub-therapeutic doses of AC.
作者简介
A. Chernov
General Medical Center of the Bank of Russia; Russian Medical Academy of Continuous Professional Education
编辑信件的主要联系方式.
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
SPIN 代码: 5893-5394
врач-терапевт отд. управления качеством медицинской помощи ММЦ Банка России, ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowE. Kleymenova
General Medical Center of the Bank of Russia; Russian Medical Academy of Continuous Professional Education; Federal Research Center “Computer Science and Control”
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-8745-6195
д.м.н., зав. отд. управления качеством медицинской помощи ММЦ Банка России, проф. каф. клинической фармакологии и терапии им. акад. Б.Е. Вотчала ФГБОУ ДПО РМАНПО, ФИЦ ИУ
俄罗斯联邦, MoscowD. Sychev
Russian Medical Academy of Continuous Professional Education
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-4496-3680
чл.-кор. РАН, д.м.н., проф., ректор ФГБОУ ДПО РМАНПО, зав. каф. клинической фармакологии и терапии им. акад. Б.Е. Вотчала ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowL. Yashina
General Medical Center of the Bank of Russia; Federal Research Center “Computer Science and Control”
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0003-1357-0056
к.б.н., консультант отд. управления качеством медицинской помощи ММЦ Банка России, зав. отд. Института современных информационных технологий в медицине ФИЦ ИУ РАН
俄罗斯联邦, MoscowM. Nigmatkulova
Russian Medical Academy of Continuous Professional Education
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-8840-4904
врач, клинический фармаколог отд. управления качеством ММЦ Банка России
俄罗斯联邦, MoscowV. Otdelenov
General Medical Center of the Bank of Russia; Russian Medical Academy of Continuous Professional Education
Email: sbornaya1med@yandex.ru
SPIN 代码: 8357-5770
к.м.н., ММЦ Банка России, ФГБОУ ДПО РМАНПО
俄罗斯联邦, MoscowS. Payushchik
General Medical Center of the Bank of Russia
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0002-7350-0423
SPIN 代码: 1367-6633
к.м.н., ММЦ Банка России
俄罗斯联邦, Moscow参考
- Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew Paisley study. Heart. 2001;86:516-21. doi: 10.1136/heart.86.5.516
- Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53. doi: 10.1093/eurheartj/ehi825
- Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-52. doi: 10.1161/01.CIR.98.10.946
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. doi: 10.7326/0003-4819-146-12-200706190-00007
- Lowres N, Giskes K, Hespe C, et al. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circulation J. 2019;49(10):883-907. doi: 10.4070/kcj.2019.0234
- Kapoor A, Amroze A, Golden J, et al. SUPPORT-AF: Piloting a multi-faceted, electronic medical record-based intervention to improve prescription of anticoagulation. J Am Heart Assoc. 2018;7(17):e009946. doi: 10.1161/JAHA.118.009946
- Wertheimer G, Bereznicki LR. Exploring the quality of anticoagulant prescribed for patients with atrial fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia. J Cardiovasc Pharmacol Ther. 2019;24(1):46-53. doi: 10.1177/1074248418786264
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi: 10.1056/NEJMoa1107039
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi: 10.1056/NEJMoa1009638
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi: 10.1056/NEJMoa0905561
- Karlsson LO, Nilsson S, Charitakis E, et al. Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting. Am Heart J. 2017;187:45-52. doi: 10.1016/j.ahj.2017.02.009
- Sheibani R, Sheibani M, Heidari-Bakavoli A, et al. The effect of a clinical decision support system on improving adherence to guideline in the treatment of atrial fibrillation: an interrupted time series study. J Med Syst. 2017;42(2):26. doi: 10.1007/s10916-017-0881-6
- Nieuwlaat R, Barker L, Kim YK, et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res. 2010;125(4):e128-31. doi: 10.1016/j.thromres.2009.11.007
- Steinberg BA, Kim S, Fonarow GC, et. al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;167:735-42.e2. doi: 10.1016/j.ahj.2014.02.003
- Назаренко Г.И., Пающик С.А., Отделенов В.А. и др. Оптимизация профилактики венозных тромбозов и эмболий в стационаре с использованием информационных технологий. Рац. фармакотерапия в кардиологии. 2014;10(4):425-31 [Nazarenko GI, Payushik SA, Otdelenov VA, et al. Optimal prevention of hospital venous thromboembolism with the information technologies. Rational Pharmacotherapy in Cardiology. 2014;10(4):425-31 (In Russ.)]. doi: 10.3233/JRS-150709
- Назаренко Г.И., Клейменова Е.Б., Жуйков М.Ю. и др. Система автоматизации клинических руководств и лечения. Врач и информ. технологии. 2014;2:23-31 [Nazarenko GI, Kleymenova EB, Zhujkov MYu, et al. System of computer-interpretable clinical guidelines and treatment audit. Vrach I Informatsionnye technoligii. 2014;2:23-31 (In Russ.)]. doi: 10.14357/20718632190107
- Ревишвили А.Ш., Шляхто Е.В., Сулимов В.А. и др. Диагностика и лечения фибрилляции предсердий. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА). М., 2017; с. 466-528 [Revishvili A.Sh, Shlyakhto EV, Sulimov VA et al. Diagnostics and treatment of atrial fibrillation. Clinical guidelines for electrophysiological studies, catheter ablation and the use of implantable antiarrhythmic devices. All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Cardiac Stimulation. Moscow, 2017; p. 466-528 (In Russ.)]. http://www.ismp.org/tools/highalertmedications.pdf
- European Society of Cardiology. European Heart Rhythm Association. Guidelines for the management of atrial fibrillation, 2016. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210
- Российское Министерство здравоохранения. Государственный реестр лекарственных средств [Russian Ministry of Health. State Register of Medicines (In Russ.)]. http://www.grls.rosminzdrav.ru/Default.aspx
- Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100. doi: 10.1378/chest.10-0134
- Classification for drug related problems V8.02. Pharmaceutical Care Network Europe Foundation; 2003−2017. https://www.pcne.org/upload/ files/230_PCNE_classification_V8-02.pdf
- Huisman MV, Rothman KJ, Paquette M. The Changing landscape for stroke prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777-85. doi: 10.1016/j.jacc.2016.11.061
- Angel Y, Zeltser D, Berliner S. Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation. Br J Clin Pharmacol. 2019;85(12):2838-47. doi: 10.1111/bcp.14116
补充文件
